Article
A more thoughtful approach to antimicrobial prophylaxis is to obtain rectal swab cultures ahead of time and determine which bacteria are susceptible to antibiotics.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Experts share insights on next-generation NMIBC therapies
Study shows value of precision-based approaches in prostate cancer
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC